GoodRx sees 2024 revenue $800M-$810M, consensus $800.99M

Sees adjusted EBITDA greater than $250M. “For the second quarter of 2024, we are guiding to revenue and Adjusted Revenue of approximately $200 million, representing approximately 5% year-over-year growth, and Adjusted EBITDA Margin in the low thirty-percent range,” said Karsten Voermann, Chief Financial Officer. “For the full year 2024, we are raising our guidance for revenue and Adjusted Revenue to be between $800 million and $810 million, representing approximately 6% growth on an adjusted basis at the midpoint. The full year growth rate has been tempered by approximately $15 million of top-line impact associated with the de-prioritization of vitaCare, as well as the anticipated sunset of the Kroger Savings Club. Additionally, contra-revenue related to consumer incentives is expected to increase by almost $10 million this year. In aggregate, this anticipated $25 million of top-line impact is absorbed in the full year $800 million to $810 million revenue and Adjusted Revenue guidance, as is the ongoing full year effect of the Change Healthcare outage with its expected low-single-digit million-dollar impact. We expect to achieve over $250 million of Adjusted EBITDA for the full year, up about 15% from 2023.”